Antififi brinolytics in liver surgery

Indian Journal of Anaesthesia

Volumn 54, Issue 6, 2010, Pages 489-495

  Makwana, Jalpa ^a   Paranjape, Saloni ^a   Goswami, Jyotsna ^a  

^a JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

Antifibrinolytic drugs; Blood transfusion; Hyperfibrinolysis; Orthotopic liver transplantation

Indexed keywords

AMINOCAPROIC ACID DERIVATIVE; ANTIFIBRINOLYTIC AGENT; APROTININ; DESMOPRESSIN; EPISILON AMINOCAPROIC ACID; FRESH FROZEN PLASMA; LYSINE; NAFAMSTAT MESILATE; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SERINE PROTEINASE INHIBITOR; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

BLEEDING; COCHRANE LIBRARY; DRUG DOSE COMPARISON; DRUG INDICATION; ERYTHROCYTE TRANSFUSION; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INCIDENCE; INDIVIDUALIZATION; INTRAOPERATIVE PERIOD; LIVER ARTERY THROMBOSIS; LIVER SURGERY; LIVER TRANSPLANTATION; LOW DRUG DOSE; MEDLINE; MORTALITY; PATIENT SELECTION; PERIOPERATIVE COMPLICATION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

EID: 79251475291     PISSN: 00195049     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-5049.72636     Document Type: Review

References (54)

1. De Boer MT, Christensen MC, Asmussen M, van der Hilst CS, Hendriks HG, Slooff MJ, et al. The impact of intraoperative transfusion of platelets and red blood Cells on survival after liver transplant. Anesth Analg 2008;106:32-44.
2. th ed. Philadelphia: Churchill Livingstone Elsvier; 2010. p. 2155-84.
3. Kang Y, Lewis JH, Navalgund A, Russell MW, Bontempo FA, Niren LS, et al. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 1987;66:766-73.
4. Kasper M, Ramsay MA, Nguyen AT, Cogswell M, Hurst G, Ramsey KJ. Continuous small-dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation. Anesth Analg 1997;85:281-5.
5. Porte RJ, Bontempo FA, Knot EA, Lewis JH, Kang YG, Starzl TE. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation 1989;47:978-84.
6. Wu CC, Ho WN, Cheng SB, Yeh DC, Wen Mc, Liu TJ, et al. Perioperative parenteral tranexamic acid in liver tumor resection. Ann Surg 2006;243:173-80.
7. Sun Z, Chen Y, Wang P, Zhang J, Gurewich V, Zhang P, et al. The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinaseinduced plasminogen activation. Biochim Biophys Acta 2002;1596:182-92.
8. Wells PJ. Safety and efficacy of methods for reducing perioperative allogeneic transfusion: a critical review of the literature. Am J Ther 2002;9:377-88.
9. Verstraete M. Clinical application of inhibition of fibrinolysis. Drugs 1985;29:236-61.
10. Hardy J, Desroches J. Natural and synthetic antifibrinolytics in cardiac surgery. Can J Anaesth 1992;39:353-65.
11. Robert S, Wagner BKJ, Boulanger M, Richer M. Aprotinin. Ann Pharmacother 1996;30:372-80.
12. Peters DC, Noble S. Aprotinin - an update of its pharmacology and therapeutic use in open heart Surgery and coronary artery bypass surgery. Drugs 1999;57:233-60.
13. Landis RC, Asimakopoulos G, Poullis M, Haskard DO, Taylor KM. The antithrombolic and anti-inflammatory mechanisms of action of aprotinin. Ann Thorac Surg 2001;72:2169-75.
14. Fergusson DA, Herbert PC, Mazer D, Fremes S, MacAdams C, Murkinn JN, et al. A comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery. N Eng J Med 2008;358:2319-31.
15. FDA-Available from: http://www.fda.gov/cder/drug/infopage/aprotinin/default.htm [last accessed on 2010 Feb 5].
16. Von Kaulla KN, Kaye H, Von Kaulla E, Marchioro TL, Starzl TE. Changes in blood coagulation, before and after hepatectomy or transplantation in dogs and man. Arch Surg 1966;92:71-9.
17. Dalmau A, Sabate A, Acosta F, Garcia-Huete L, Koo M, Sansano T, et al. Tranexamic acid reduces red cell transfusion better than aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000;91:29-34.
18. Carlier M, Veyckemans F, Scholtes JL, Gouverner JM, Gribomont BF, Moulin D, et al. Anesthesia for pediatric hepatic transplantation;experience of 33 cases. Transplant Proc 1987;19:3333-7.
19. Boylan JF, Klinck JR, Sandler AN, Arellano R, Greig PD, Nierenberg H, et al. Tranexamic acid use reduces blood loss, transfusion requirements, and coagulation factor in primary orthotopic liver transplantation. Anesthesiology 1996;85:1043-8.
20. Dalmau A, Sabate A, Koo M, Bartolome C, Rafecas A, Figueras J, et al. The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: a comparative study. Liver Transpl 2004;10:279-84.
21. Neuhaus P, Bechstein WO, Lefebre B, Blumhardt G, Slama K. Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. Lancet 1989;2:924-5.
22. Patrassi GM, Viero M, Sartori MT, De Silvestro G, Rossaro L, Burra P, et al. Aprotonin efficacy on intraoperative bleeding and transfusion requirements in orthotopic liver transplantation. Transfusion 1994;34:507-11.
23. Marcel RJ, Stegall WC, Suit CT, Arnold JC, Vera RL, Ramsay MA, et al. Continuous small-dose aprotinin controls fibrinolysis during orthotopic transplantation. Anesth Analg 1996;82:1122-5.
24. Molenaar IQ, Begliomini B, Martinelli G, Putter H, Terpstra O, Porte RJ. Reduced need for vasopressors in patients receiving aprotinin during orthotopic liver transplantation. Anesthesiology 2001;94:433-8.
25. Devi A S, Kapoor D, Gopal PB, Subrahmanyam M, Ravichandra RS. Effect of antifibriolytic drugs on transfusion requirement and blood loss during orthotopic liver transplantation: Results from a single centre. Asian J Transfus Sci 2008;2:61-5.
26. Porte RJ, Molenaar IQ, Begliomini B, Gorenland TH, Januszkievicz A, Lindgren L, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. Lancet 2000;355:1303-9.
27. Liu CM, Chen J, Wang XH. Requirement for transfusion and Postoperative outcomes in orthotopic liver transplantation: A meta-analysis on Aprotinin. World J Gastroenterol 2008;14:1425-9.
28. Soilleux H, Gillon M, Mirand A, Daibes M, Leballe F, Ecoffey C. Comparative effects of small and large aprotinin doses on bleeding during orthotopic liver transplantation. Anesth Analg 1995;80:349-52.
29. Garcia-Huete L, Domenech P, Sabate A, Matinez-Brotons F, Jaurrieta E, Figueras J. The prophylactic effect of aprotinin on intraoperative bleeding in liver transplantation: a randomized clinical study. Hepatology 1997;26:1143-8.
30. Milroy SJ, Cottam S, Tan KC, Hilmi I, Oyesola B. Improved haemodynamic stability with administration of aprotinin during orthotopic liver transplantation. Br J Anaesth 1995;75:747-51.
31. Lentschner C, Benhamou D, Mercier FJ, Boyer-Neumannc C, Naeau S, Smajd C, et al. Aprotonin reduces blood loss in patiets undergoing elective liver resection. Anesth Analg 1997;84:875-81.
32. Lentschener C, Roche K, Ozier Y. A review of Aprotinin in Orthoopic Liver Transplantation: Can its Harmful Effects Offset Its Beneficial Effects? Anesth Analg 2005;100:1248-55.
33. Xia VW, Steadman RH. Antifibrinolytics in orthotopic liver transplantation: Liver Transpl 2005;11:10-8.
34. Molenaar IQ, Warnaar N, Groen H, Tenvergert EM, Slooff MJ, Porte RJ. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systemic review and meta-analysis. Am J Transplant 2007;7:185-94.
35. Pereboom IT, de Boer MT, Porte RJ, Molenaar IQ. Aprotonin and Nafamostat mesilate in liver surgery: effect on blood loss. Dig Surg 2007;24:282-7.
36. Dalmau A, Sabate A, Aparicio I. Hemostasis and coagulation monitoring and management during liver transplantation. Curr Opin Organ Transplant 2009;14:286-90.
37. Gurusamy KS, Li J, Sharma D, Davidson BR. Pharmacological interventions to decrease blood loss and transfusion requirements for liver resection. Cochrane Database Syst Rev 2009;7:CD008085.
38. Gologorsky E, De Wolf AM, Scott V, Aggarwal S, Dishart M, Kang Y. Intracardiac thrombus formation and pulmonary thromboembolism immediately after reperfusion in 7 patients undergoing liver transplantation. Liver Transpl 2001;9:783-9.
39. Warnaar N, Molenaar IQ, Colquhoun SD, Slooff MJ, Sherwani S, de Wolf AM, et al. Intraoperative pulmonary embolism and intracardiac thrombosis complicating liver transplantation: a systematic review. J Thromb Haemost 2008;6:297-302.
40. Navalgund AA, Kang Y, Sarner JB, Jahr JS, Gieaerts R. Massive pulmonary thromboembolism during liver transplantation. Anesth Analg 1988;67:400-2.
41. Baubillier E, Cherqui D, Dominique C, Khalil M, Bonnet F, Fagniez PL, et al. A fatal thrombotic complication during liver transplantation after aprotinin administration. Transplantation 1994;57:1664-6.
42. Prah GN, Lisman SR, Maslow AD, Freeman RB, Rohrer RJ. Transesophageal echocardiography reveals an unusual cause of hemodynamic collapse during Orthotopic liver transplantationtwo case reports. Transplantation 1995;59:921-5.
43. Sopher M, Braunfeld M, Shackleton C, Busutil RW, Sangwan S, Csete M. Fatal pulmonary embolism during liver transplantation. Anesthesiology 1997;87:429-32.
44. Manji M, Isaac JL, Bion J. Survival from massive intraoperative pulmonary thrombo embolism during orthotopic liver transplantation. Br J Anaesth 1998;80:685-7.
45. Fitzsimons MG, Peterfreund RA, Raines DE. Aprotinin administration and pulmonary thromboembolism during orthotopic liver transplantation: report of two cases. Anesth Analg 2001;92:1418-21.
46. O'Connor CJ, Roozeboom D, Brown R, Tuman KJ. Pulmonary thromboembolism during liver transplantation: possible association with antifibrinolytic drugs and novel treatment options. Anesth Analg 2002;91:296-9.
47. Wong WH, Braunfeld M, Levin P. Recurrent pulmonary embolism during liver transplantation: possible role of hepatitis B immune globulin as a causative agent. Anesthesiology 2002;96:1261-3.
48. Planinsic RM, Nicolau-Raducu R, Eghtesad B, Marcos A. Diagnosis and treatment of intracardiac thrombosis during orthotopic liver transplantation. Anesth Analg 2004;99:353-6.
49. Ramsay MA, Randall HB, Burton EC. Intravascular thrombosis and thromboembolism during liver transplantation: antifibrinolytic therapy implicated? Liver Transpl 2004;10:310-4.
50. Lerner AB, Sundar E, Mahmood F, Sarge T, Hanto DW, Panzica PJ. Four cases of cardiopulmonary thromboembolism during liver transplantation without the use of antifibrinolytic drugs. Anesth Analg 2005;101:1608-12.
51. Jackson D, Botea A, Gubenko Y, Delphin E, Bennett H. Successful Intraoperative use of recombinant tissue plasminogen activator during liver transplantation complicated by massive intracardiac/pulmonary thrombosis. Anesh Analg 2006;102:724-8.
52. Freise CE, Gillespie BW, Koffron AJ, Lok ASF, Pruett TL, Emond JC, et al. Recipient morbidity after living and deceased donor liver transplantation: findings from the A2ALL retrospective chort study. Am J Transplant 2008;8:2569-79.
53. Khalaf H. Vascular complications after deceased and living donor liver transplantation: a single-centre experience. Transplant Proc 2010;42:865-70.
54. Bekker J, Ploem S, de Jong KP. Early hepatic artery thrombosis after liver transplantation: a systematic review of the incidence, outcome and risk factors. Am J Transplant 2009;9:746-57.